Piper Sandler lowers UnitedHealth Group stock price target to $317 on earnings outlook

UnitedHealth Group (UNH) has seen its stock decline significantly year-to-date following a Q2 EPS miss and a lower-than-expected adjusted EPS outlook of $16.00 for calendar year 2025, falling short of market estimates, despite robust 13% revenue growth. While some analysts, like Piper Sandler, have reduced price targets, they maintain an 'Overweight' rating, recommending buying on weakness given the company's transparent remediation plan targeting high-teens EPS growth by 2026-2027. However, UNH itself anticipates continued pricing pressure, elevated medical costs, and negative Medicaid margins through 2026, signaling ongoing challenges.

Analysis

UnitedHealth Group (UNH) is facing significant investor concern following a substantial stock price decline of nearly 44% year-to-date, exacerbated by a mixed second-quarter financial report. The company missed earnings expectations with an EPS of $4.08 against a consensus of $4.45, an 8.31% shortfall. More critically, management set a calendar year 2025 adjusted EPS floor of $16.00, substantially below the market's anticipated $18.00-$19.00 range. UNH itself has signaled persistent headwinds, projecting ongoing pricing pressure, elevated medical cost trends, and negative margins in its Medicaid business through 2026. Despite these challenges, the company posted strong top-line growth with a 13% year-over-year revenue increase to $112 billion and maintains strong fundamentals, including a P/E ratio of 11.03 and a robust free cash flow yield. Analyst sentiment is divided; while BofA Securities lowered its price target to $300 citing a slow recovery, Piper Sandler maintains an 'Overweight' rating, viewing the weakness as a buying opportunity based on management's transparent remediation plan, which it believes could support a high-teens EPS compound annual growth rate in 2026-2027.

Key Decisions for Investors

• Investors should weigh the attractive valuation, highlighted by a P/E of 11.03 and strong free cash flow, against the significant near-term risk from lowered 2025 EPS guidance and persistent medical cost pressures.
• A long-term investment thesis is contingent on management's ability to execute its multi-year remediation plan, making the stock suitable for investors with a higher risk tolerance and a time horizon extending to 2026-2027.
• Key metrics to monitor closely are medical cost trends and company disclosures on its Medicaid business, as management has explicitly flagged expectations of negative margins in that segment by 2026.
• The considerable divergence in analyst price targets, from $300 to $350, reflects deep uncertainty about the recovery timeline, warranting caution and a thorough assessment of the company's path to improved profitability.